Results 311 to 320 of about 1,997,971 (386)
The Activation of Phosphorylase in Neonatal Rat Liver
Max H. Cake, I.T. Oliver
openalex +1 more source
Objective To assess risks of adverse pregnancy outcomes (APOs) in a contemporary cohort of women with systemic sclerosis (SSc) in relation to the timing of SSc diagnosis and by parity. Methods From the nationwide Swedish Medical Birth Register, we assembled pregnancies with births in women with SSc and in comparator women from the general population ...
Weng Ian Che +5 more
wiley +1 more source
Comparison of postpartum depression, anxiety, sleep quality and neonatal outcomes in mothers with pregestational and gestational diabetes. [PDF]
Aycan OK, Aksu SC.
europepmc +1 more source
Objective The transition from asymptomatic anti‐nuclear antibody (ANA) positivity to systemic autoimmune rheumatic disease (SARD) is associated with increased production of pro‐inflamamtory factors such as TNF‐α. Here we investigate whether the relative absence of inflammation in asymptomatic ANA+ individuals (ANA+NS) results from a lack of circulating
Carolina Muñoz‐Grajales +8 more
wiley +1 more source
The role of machine learning methods in assessing the risk of neonatal sepsis: A study of biochemical markers and genetic variants. [PDF]
Zhao X +5 more
europepmc +1 more source
Objective International criteria for antiphospholipid syndrome (APS) include lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin (Ig) G and IgM, and anti‐β2‐glycoprotein I (β2GPI) IgG and IgM. However, evidence supporting their prognostic value or treatment efficacy in improving live birth rates is limited.
Megumi Nonobe +8 more
wiley +1 more source
Neonatal Gonococcal Conjunctivitis Caused by Fluoroquinolone-Resistant Neisseria gonorrhoeae. [PDF]
Mizushima H +3 more
europepmc +1 more source
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source

